Cogent Biosciences, Inc.

Cogent Biosciences, Inc. is a biotechnology company focused on discovering and developing therapeutic drug candidates. The company's principal development program centers on bezuclastinib, a targeted product candidate undergoing clinical trials, alongside several early-stage discovery and preclinical research programs. Cogent Biosciences designs its drug candidates to address specific clinical conditions, targeting patient populations in need of novel treatments. The company aims to provide its therapies to healthcare providers, physicians, patients, and third-party healthcare payors upon receiving necessary regulatory approvals.

The company is incorporated in Delaware and maintains its corporate headquarters in Waltham, Massachusetts. Its physical footprint includes leased office and laboratory facilities located in Waltham, Massachusetts, and Boulder, Colorado. Cogent Biosciences conducts its drug development operations primarily in the United States, coordinating clinical trials, regulatory submissions, and research activities with regulatory authorities such as the Food and Drug Administration.

Summary of the business section of Cogent Biosciences's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 258 employees.”